Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJiazhuo LiuCHChuan He

Discussion

Loading...

Member takes

Overview

Retrospective study shows improved clinical efficacy and safety profile of orelabrutinib in CLL, suggesting its benefit in first-line therapy.

Key Points

  • This research aims to evaluate the efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia (CLL).
  • Retrospective review of CLL patients treated with orelabrutinib monotherapy
  • Clinical data analyzed included overall response rate, survival outcomes, and adverse events
  • Patient characteristics and treatment response were descriptively assessed
  • 28 out of 30 patients achieved an overall response, with 4 complete responses
  • Median progression-free survival and overall survival rates were not reached during follow-up
  • The study observed a favorable safety profile with minimal off-target effects

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbfdhttps://doi.org/10.1182/blood-2025-7422
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma2025
  2. 2Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.2026
  3. 3Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations
  4. 4Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  5. 5Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations